

Complete if Known

Attorney Docket Number	2003P88073 US
------------------------	---------------

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

[illegible][illegible]

8/1/06

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

DNR: 7057 / V: 04-1.00 / B: Val

Substitute for form 1449/PTO
(Revised 04/2003)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number
Filing Date
First Named Inventor
Group Art Unit
Examiner Name

Concurrently Herewith

Walsh et al.

Sheet 1 of 3 Attorney Docket Number 046242/270382

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
GR	1	US-3,894,000	07/08/1975	Wechter et al.	
	2	US-4,425,335	01/10/1984	Fujii et al.	
	3	US-4,490,366	12/25/1984	Fujii et al.	
	4	US-4,503,045	03/05/1985	Fujii et al.	
	5	US-4,599,404	07/08/1986	Fujii et al.	
	6	US-4,681,933	07/21/1987	Chu et al.	
	7	US-4,757,139	07/12/1988	Kawaguchi et al.	
	8	US-4,886,877	12/12/1989	Fujii et al.	
	9	US-4,904,770	02/27/1990	Starrett, Jr. et al.	
	10	US-4,908,440	03/13/1990	Sterzycki et al.	
	11	US-4,910,300	03/20/1990	Urdea et al.	
	12	US-4,921,950	05/01/1990	Wilson	
	13	US-4,937,329	06/26/1990	Reese	
	14	US-5,013,828	05/07/1991	Kikuchi et al.	
	15	US-5,070,078	12/03/1991	Selway et al.	
	16	US-5,093,232	03/03/1992	Urdea et al.	
	17	US-5,101,023	03/31/1992	Czernecki et al.	
	18	US-5,126,506	06/30/1992	Sterzycki et al.	
	19	US-5,179,200	01/12/1993	Molko et al.	
	20	US-5,190,926	03/02/1993	Chu et al.	
GR	21	US-5,204,456	04/20/1993	Molko et al.	
Examiner Signature	G. K. [Signature]		Date Considered	8/1/06	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 04/2003) INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
Examiner Name					
Sheet	2	of	3	Attorney Docket Number 046242/270382	
U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
CK	22	US-5,212,293	05/18/1993	Green et al.	
	23	US-5,218,106	06/08/1993	Sterzycki et al.	
	24	US-5,359,053	10/25/1994	Rogers et al.	
	25	US-5,428,148	06/27/1995	Reddy et al.	
	26	US-5,466,787	11/14/1995	Chen et al.	
	27	US-5,530,110	06/25/1996	Sowers	
	28	US-5,608,048	03/04/1997	Gandhi et al.	
	29	US-5,608,049	03/04/1997	Spector et al.	
	30	US-5,646,269	07/08/1997	Matteucci et al.	
	31	US-5,672,698	09/30/1997	Chen et al.	
	32	US-5,679,785	10/21/1997	Engels et al.	
	33	US-5,717,086	02/10/1998	Chambers et al.	
	34	US-5,760,208	06/02/1998	Abushanab et al.	
	35	US-5,932,719	08/03/1999	Abushanab et al.	
	36	US-6,060,592	05/09/2000	Acevedo et al.	
	37	US-6,121,438	09/19/2000	Abushanab et al.	
	38	US-6,326,491	12/04/2001	Abushanab et al.	
	39	US-6,362,329	03/26/2002	Abushanab et al.	
	40	US-6,369,040	04/09/2002	Acevedo et al.	
	41	US-2003/0004331 A1	01/02/2003	Komatsu et al.	
CK	42	US-2003/0087873 A1	05/08/2003	Stuyver et al.	
Examiner Signature		G. Kriz		Date Considered	8/1/06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 04/2003)		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	
		Filing Date	Concurrently Herewith
		First Named Inventor	Walsh et al.
		Group Art Unit	
		Examiner Name	
Sheet 3 of 3	Attorney Docket Number	046242/270382	
OTHER DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
GC	43	Balogpala et al., "An Improved Synthesis of Azidothymidine," <u>Nucleosides & Nucleotides</u> , 15(4), pp. 899-906, 1996	
	44	Varagnolo et al., " ¹⁸ F-labeled Radiopharmaceuticals for PET in Oncology, Excluding FDG," <u>Nuclear Medicine & Biology</u> , Vol. 27, pp. 103-112, 2000	
	45	Martin et al., "A new precursor for the radiosynthesis of [¹⁸ F]FLT," <u>Nuclear Medicine & Biology</u> , 29, pp. 263-273, 2002	
	46	Grierson et al., "Radiosynthesis of 3'-Deoxy-3'-[¹⁸ F]fluorothymidine: [¹⁸ F]FLT for Imaging of Cellular Proliferation <i>in Vivo</i> ," <u>Nuclear Medicine & Biology</u> , Vol. 27, pp. 143-156, 2000	
	47	Yun et al., "High radiochemical yield synthesis of 3'-deoxy-3'-[¹⁸ F]fluorothymidine using (5'-O-dimethoxytrityl-2'-deoxy-3'-O-nosyl-β-D-threo pentofuranosyl)thymine and its 3-N-BOC-protected analogue as a labeling precursor," <u>Nuclear Medicine & Biology</u> , 30, pp. 151-157, 2003	
	48	Shields et al., "Imaging Proliferation <i>in vivo</i> with [F-18]FLT and positron emission tomography," <u>Nature Medicine</u> , Volume 4, Number 11, pp. 1334-1336, November, 1998	
	49	Blocher et al., "Synthesis and labeling of 5'-O-(4,4'-dimethoxytrityl)-2,3'-anhydrothymidine for [¹⁸ F]FLT preparation," <u>Journal of Radioanalytical and Nuclear Chemistry</u> , Vol. 251, No. 1, pp. 55-58, 2002	
	50	Machulla et al., "Simplified labeling approach for synthesizing 3'-deoxy-3'-[¹⁸ F]fluorothymidine ([¹⁸ F]FLT)," <u>Journal of Radioanalytical and Nuclear Chemistry</u> , Vol. 243, No. 3, pp. 843-846, 2000	
	51	Wodarski et al., "Synthesis of 3'-Deoxy-3'-[¹⁸ F]Fluoro-Thymidine with 2,3'-Anhydro-5'-O-(4,4'-Dimethoxytrityl)-Thymidine," <u>Journal of Labelled Compounds and Radiopharmaceuticals</u> , 43, pp. 1211-1218, 2000	
GC	52	Vesselle et al., " <i>In Vivo</i> Validation of 3'-deoxy-3'-[¹⁸ F]fluorothymidine ([¹⁸ F]FLT) as a Proliferation Imaging Tracer in Humans: Correlation of [¹⁸ F]FLT Uptake by Positron Emission Tomography with Ki-67 Immunohistochemistry and Flow Cytometry in Human Lung Tumors," <u>Clinical Cancer Research</u> , Vol. 8, pp. 3315-3323, November, 2002	
Examiner Signature	G. Karim		Date Considered
		8/1/06	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. CLT01/46239351v1